Pharmacogenetics in the clinic

Por Guchelaar, H.-J.
Publicado em 2013

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease

Por Krens, L. L., Baas, J. M., Guchelaar, H. J., Gelderblom, H.
Publicado no Cancer Chemother Pharmacol (2017)

Regarding: ‘Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array’

Por Pander, J, Gelderblom, H, van der Straaten, T, Punt, C J A, Guchelaar, H-J
Publicado em 2010

PROCEEDINGS OF THE DUTCH SOCIETY FOR CLINICALPHARMACOLOGY AND BIOPHARMACY 7 April 2000

Por VERMES, A, MATHÔT, R A A, VAN DER SIJS, I H, DANKERT, J, GUCHELAAR, H-J
Publicado em 2000

UGT1A1(*)28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study

Por Kweekel, D M, Gelderblom, H, Van der Straaten, T, Antonini, N F, Punt, C J A, Guchelaar, H-J
Publicado em 2008

Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis

Por van Kan, H J M, Groeneveld, G J, Kalmijn, S, Spieksma, M, van den Berg, L H, Guchelaar, H J
Publicado em 2005

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.

Por Guchelaar, H. J., Hoekstra, H. J., de Vries, E. G., Uges, D. R., Oosterhuis, J. W., Schraffordt Koops, H.
Publicado em 1992

Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array

Por Kweekel, D M, Antonini, N F, Nortier, J W R, Punt, C J A, Gelderblom, H, Guchelaar, H-J
Publicado em 2009

CYP2D6 Metabolism in Frail Elderly Compared to Non-Frail Elderly: A Pilot Feasibility Study

Por Opdam, F. L., Modak, A. S., Mooijaart, S. P., Louwerens, M., de Waal, M. W. M., Gelderblom, H., Guchelaar, H.-J.
Publicado no Drugs Aging (2015)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism

Por Sanchez Spitman, A. B., Moes, D. J. A. R., Gelderblom, H., Dezentje, V. O., Swen, J.J., Guchelaar, H. J.
Publicado no Eur J Clin Pharmacol (2017)

Nasal drug delivery to the cerebrospinal fluid: transport of a lipophilic compound

Por Merkus, P, Guchelaar, H J, Van Rijn-Bikker, P C, Sastre Toraño, J, Bosch, D A, Merkus, F W H M
Publicado em 2002

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients

Por Baas, J. M., Krens, L. L., ten Tije, A. J., Erdkamp, F., van Wezel, T., Morreau, H., Gelderblom, H., Guchelaar, H. J.
Publicado no Invest New Drugs (2015)

Relative Bioavailability of Three Newly Developed Albendazole Formulations: a Randomized Crossover Study with Healthy Volunteers

Por Rigter, I. M., Schipper, H. G., Koopmans, R. P., Kan, H. J. M. van, Frijlink, H. W., Kager, P. A., Guchelaar, H.-J.
Publicado em 2004

Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers

Por van Rongen, A, Kervezee, L, Brill, MJE, van Meir, H, den Hartigh, J, Guchelaar, H-J, Meijer, JH, Burggraaf, J, van Oosterhout, F
Publicado no CPT Pharmacometrics Syst Pharmacol (2015)

GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group

Por Kweekel, D M, Koopman, M, Antonini, N F, Van der Straaten, T, Nortier, J W R, Gelderblom, H, Punt, C J A, Guchelaar, H-J
Publicado em 2008

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19

Por Swen, J. J., van der Straaten, T., Wessels, J. A. M., Bouvy, M. L., Vlassak, E. E. W., Assendelft, W. J. J., Guchelaar, H.-J.
Publicado em 2011

A comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group

Por Bank, P.C.D., Caudle, K.E., Swen, J.J., Gammal, R.S., Whirl-Carrillo, M., Klein, T.E., Relling, M.V., Guchelaar, H.-J.
Publicado no Clin Pharmacol Ther (2017)

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

Por Gietema, J. A., de Vries, E. G., Sleijfer, D. T., Willemse, P. H., Guchelaar, H. J., Uges, D. R., Aulenbacher, P., Voegeli, R., Mulder, N. H.
Publicado em 1993

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.

Por Gietema, J. A., Veldhuis, G. J., Guchelaar, H. J., Willemse, P. H., Uges, D. R., Cats, A., Boonstra, H., van der Graaf, W. T., Sleijfer, D. T., de Vries, E. G.
Publicado em 1995

A pharmacological rationale for improved everolimus dosing in oncology and transplant patients

Por ter Heine, R., van Erp, N. P., Guchelaar, H. J., de Fijter, J. W., Reinders, M. E. J., van Herpen, C. M., Burger, D. M., Moes, D. J. A. R.
Publicado no Br J Clin Pharmacol (2018)